RU2005115448A - Агонисты рецепторов нейромедина в и соматостатина - Google Patents
Агонисты рецепторов нейромедина в и соматостатина Download PDFInfo
- Publication number
- RU2005115448A RU2005115448A RU2005115448/04A RU2005115448A RU2005115448A RU 2005115448 A RU2005115448 A RU 2005115448A RU 2005115448/04 A RU2005115448/04 A RU 2005115448/04A RU 2005115448 A RU2005115448 A RU 2005115448A RU 2005115448 A RU2005115448 A RU 2005115448A
- Authority
- RU
- Russia
- Prior art keywords
- cys
- trp
- lys
- cyclo
- nal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Addiction (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
Claims (8)
1. Соединение формулы (IV)
где AA1 является Phe или отсутствует;
AA2 означает Phe или Trp;
AA3 означает D-изомер Trp;
AA4 означает Lys;
AA5 является Pal или отсутствует;
AA6 означает Thr или L-Phe;
AA7 отсутствует; и
AA8 означает R11;
R1 представляет собой H;
R11 независимо для каждого случая является D- или L-аминокислотой формулы:
где каждый из m и n независимо равны 1, 2 или 3, и р равно 0, 1 или 2;
R12 независимо для каждого случая является необязательно замещенным фрагментом формулы
Х1 означает H, (С1-6)алкил или фрагмент, который соответствует группе боковой цепи Arg, Leu, Gln, Lys, Tyr, His, Thr, Trp, Phe, Val, Ala, Lys или His;
каждый из Х2 и Х3 независимо представляет собой Н, галоген, (C1-12)алкил, фенил, фенил-(С1-6)алкил и
Х4 означает H, OH или NH2;
при условии, что присутствуют по меньшей мере шесть аминокислотных остатков;
АА1 и АА8 связаны дисульфидной связью; и,
когда АА1 отсутствует, АА2 и АА8 вместе образуют связь.
2. Соединение по п.1, где R1 и R5 отсутствуют, и N-концевая аминокислота и C-концевая аминокислота вместе образуют амидную связь; или его фармацевтически приемлемая соль.
3. Соединение по п.1, где R1 и R5 отсутствуют, и N-концевая аминокислота и C-концевая аминокислота вместе образуют амидную связь; или его фармацевтически приемлемая соль.
4. Соединение по п.1, где указанное соединение соответствует формуле
цикло(Trp-D-Trp-Lys-Phe(4-О-Bzl)-Phe-(T)aeg);
цикло(Trp-D-Trp-Lys-Pal-Phe-(T)aeg); или
цикло(Phe-Phe-D-Trp-Lys-Thr-(T)aeg);
или его фармацевтически приемлемая соль.
5. Способ, позволяющий вызывать агонистическое действие со стороны рецептора соматостатина у пациента, который в этом нуждается, при этом указанный способ включает в себя введение указанному субъекту эффективного количества соединения по п.4 или его фармацевтически приемлемой соли, при условии, что указанное соединение не является
цикло(Trp-D-Trp-Lys-Phe(4-О-Bzl)-Phe-(T)aeg); или
цикло(Trp-D-Trp-Lys-Pal-Phe-(T)aeg).
6. Способ, позволяющий вызывать агонистическое действие SSTR-1 у пациента, который в этом нуждается, при этом указанный способ включает в себя введение указанному субъекту эффективного количества соединения по п.1 или его фармацевтически приемлемой соли, при условии, что указанное соединение не является
Nal-Tyr-цикло(Cys-D-Trp-Lys-D-Cys)-Val-Nal-NH2;
Nal-Tyr-цикло(Cys-D-Trp-Lys-D-Cys)-Abu-Nal-NH2;
Dip-Tyr-цикло(D-Cys-D-Trp-Lys-D-Cys)-Abu-Nal-NH2;
Nal-Tyr-цикло(D-Cys-D-Trp-Lys-D-Cys)-Abu-Nal-NH2;
Dip-Tyr-цикло(D-Cys-D-Trp-Lys-D-Cys)-Val-Nal-NH2;
Nal-Tyr-цикло(D-Cys-D-Trp-Lys-D-Cys)-Val-Nal-NH2;
Cpa-Pal-цикло(D-Cys-D-Trp-Lys-D-Cys)-A3c-Nal-NH2;
Cpa-Pal-цикло(D-Cys-D-Trp-Lys-D-Cys)-A5c-Nal-NH2;
Cpa-Pal-цикло(D-Cys-D-Trp-Lys-D-Cys)-A6c-Nal-NH2;
(G(z))aeg-цикло(D-Cys-D-Trp-Lys-D-Cys)-A5c-Nal-NH2;
D-Cpa-цикло(Cys-D-Trp-Lys-D-Cys)-A5c-Nal-NH2;
Pal-цикло(D-Cys-D-Trp-Lys-D-Cys)-A5c-Nal-NH2;
Cpa-цикло(D-Cys-D-Trp-Lys-D-Cys)-A5c-Nal-NH2;
Cpa-Pal-цикло(D-Cys-D-Trp-Lys-D-Cys)-β-Ala-Nal-NH2;
цикло(D-Cys-D-Trp-Lys-D-Cys)-A5c-Nal-NH2;
Cpa-Pal-цикло(D-Cys-D-Trp-Lys-D-Cys)-Sar-Nal-NH2;
Cpa-Pal-цикло(D-Cys-D-Trp-Lys-D-Cys)-Aic-Nal-NH2;
Cpa-Pal-цикло(D-Cys-D-Trp-Lys-D-Cys)-Gaba-Nal-NH2; или
Cpa-Pal-цикло(D-Cys-D-Trp-Lys-D-Cys)-Pro-Nal-NH2.
7. Фармацевтическая композиция, обладающая свойствами рецептора соматостатина, включающая в себя эффективное количество соединения по п.1 или его фармацевтически приемлемой соли и фармацевтически приемлемый носитель.
8. Способ лечения заболевания у субъекта, включающий в себя введение указанному субъекту терапевтически эффективного количества соединения по п.1, где указанное заболевание выбрано из группы, состоящей из рака легкого, глиомы, анорексии, гипотиреоза, гиперальдостеронизма, пролиферации H. pylori, акромегалии, рестеноза, болезни Крона, системного склероза, наружной или внутренней ложной кисты поджелудочной железы и асцита, ВИПомы, гиперплазии панкреатических островков, гиперинсулинизма, гастриномы, синдрома Золлингера-Эллисона, диареи, диарея, связанной со СПИДом, диареи, связанной с химиотерапией, склеродермии, синдрома раздраженной толстой кишки, панкреатита, непроходимости тонкой кишки, гастроэзо-фагеального рефлюкса, дуоденогастрального рефлюкса, синдрома Кушинга, гонадотропиномы, гиперпаратиреоза, болезни Грейвса, диабетической нейропатии, болезни Педжета и поликистозного заболевания яичника, рака щитовидной железы, гепатомы, лейкоза, менингиомы, раковой кахексии, ортостатической гипотензии, постпрандиальной гипотензии, панических состояний, аденом, секретирующих GH, акромегалии, аденом, секретирующих TSH, аденом, секретирующих пролактин, инсулиномы, глюкагономы, сахарного диабета, гиперлипидемии, нечувствительности к инсулину, синдрома Х, ангиопатии, пролиферативной ретинопатии, феномена "рассвета", нефропатии, секреции желудочной кислоты, пептических язв, кишечно-кожной фистулы, кожно-панкретиатической фистулы, демпинг-синдрома, синдрома водной диареи, панкреатита, опухоли, секретирующей желудочно-кишечные гормоны, ангиогенеза, артрита, отторжения аллогенного трансплантата, кровотечения при сосудистой трансплантации, портальной гипертензии, желудочно-кишечного кровотечения, ожирения и передозировки опиоидами.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13765599P | 1999-06-04 | 1999-06-04 | |
US60/137,655 | 1999-06-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2005115448A true RU2005115448A (ru) | 2006-11-20 |
Family
ID=22478469
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2002100069/04A RU2263680C2 (ru) | 1999-06-04 | 2000-06-05 | Агонисты рецепторов нейромедина в и соматостатина |
RU2005115448/04A RU2005115448A (ru) | 1999-06-04 | 2005-05-19 | Агонисты рецепторов нейромедина в и соматостатина |
RU2005115449/04A RU2005115449A (ru) | 1999-06-04 | 2005-05-19 | Агонисты рецепторов нейромедина в и соматостатина |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2002100069/04A RU2263680C2 (ru) | 1999-06-04 | 2000-06-05 | Агонисты рецепторов нейромедина в и соматостатина |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2005115449/04A RU2005115449A (ru) | 1999-06-04 | 2005-05-19 | Агонисты рецепторов нейромедина в и соматостатина |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1189941B1 (ru) |
JP (3) | JP2003501443A (ru) |
CN (1) | CN1367793A (ru) |
AR (1) | AR020862A1 (ru) |
AU (1) | AU774096B2 (ru) |
BR (1) | BR0011680A (ru) |
CA (1) | CA2376506C (ru) |
CZ (1) | CZ20014297A3 (ru) |
ES (1) | ES2401096T3 (ru) |
HU (1) | HUP0202022A3 (ru) |
IL (1) | IL146884A0 (ru) |
PL (1) | PL352968A1 (ru) |
RU (3) | RU2263680C2 (ru) |
TW (1) | TWI243177B (ru) |
WO (1) | WO2000075186A1 (ru) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003000196A2 (en) * | 2001-06-25 | 2003-01-03 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | Pharmaceutical compositions which inhibit proliferation of pituitary adenomas and method of use thereof |
US7189856B2 (en) | 2001-12-28 | 2007-03-13 | Gideon Shapiro | Non-peptide somatostatin receptor ligands |
AU2003240469A1 (en) * | 2002-05-02 | 2003-11-17 | Bayer Aktiengesellschaft | Diagnostics and therapeutics for diseases associated with neuromedin b receptor (nmb) |
CA2647986C (en) | 2006-03-31 | 2014-07-08 | Erasmus University Medical Center Rotterdam | Compositions for tumor growth control |
EP2719392B1 (en) | 2008-06-12 | 2019-07-24 | Ipsen Bioinnovation Limited | Fusion proteins for use in the treatment of acromegaly |
US10240138B2 (en) | 2008-06-12 | 2019-03-26 | Ipsen Bioinnovation Limited | Polypeptides that bind to and inhibit secretion from growth hormone secreting cells |
GB0820970D0 (en) | 2008-11-17 | 2008-12-24 | Syntaxin Ltd | Suppression of cancer |
CN102341925A (zh) | 2009-04-27 | 2012-02-01 | 东芝照明技术株式会社 | 照明装置 |
CN108659100A (zh) * | 2017-03-28 | 2018-10-16 | 上海新生源医药集团有限公司 | 具有镇痛作用的多肽及其应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4505897A (en) * | 1983-04-18 | 1985-03-19 | The Administrators Of The Tulane Educational Fund | Cyclic pentapeptides displaying somatostatin antagonism and method of treatment of mammals therewith |
EP1069137A1 (en) * | 1990-09-24 | 2001-01-17 | W.R. Grace & Co.-Conn. | Peptides having thrombospondin-like activity and their therapeutic use |
HU207104B (en) * | 1991-01-25 | 1993-03-01 | Biosignal Kutato Fejlesztoe Kf | Process for producing new somatostatin analogs inhibiting tumour growth and pharmaceutical compositions comprising such compounds |
JP3407260B2 (ja) * | 1991-08-09 | 2003-05-19 | コルベツク,ヴインフリート | ランチオニン架橋ペプチド |
US5462926A (en) * | 1992-07-27 | 1995-10-31 | Biomeasure, Inc. | Neuromedin B receptor antagonists which demonstrate selectivity |
JPH08503694A (ja) * | 1992-09-08 | 1996-04-23 | セントコー・インコーポレーテッド | ペプチド系の細胞接着阻害物質 |
ES2216290T3 (es) * | 1997-05-13 | 2004-10-16 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Somatostatina y agonistas de la somatostatina para el tratamiento de insensibilidad a la insulina y de sindrome x. |
AU1172599A (en) * | 1997-11-18 | 1999-06-07 | Chugai Seiyaku Kabushiki Kaisha | Compounds with antitumor activity |
-
2000
- 2000-06-05 HU HU0202022A patent/HUP0202022A3/hu unknown
- 2000-06-05 EP EP00939563A patent/EP1189941B1/en not_active Expired - Lifetime
- 2000-06-05 AR ARP000102776A patent/AR020862A1/es not_active Application Discontinuation
- 2000-06-05 ES ES00939563T patent/ES2401096T3/es not_active Expired - Lifetime
- 2000-06-05 IL IL14688400A patent/IL146884A0/xx unknown
- 2000-06-05 CA CA2376506A patent/CA2376506C/en not_active Expired - Fee Related
- 2000-06-05 AU AU54633/00A patent/AU774096B2/en not_active Ceased
- 2000-06-05 WO PCT/US2000/015396 patent/WO2000075186A1/en active IP Right Grant
- 2000-06-05 CN CN00811215A patent/CN1367793A/zh active Pending
- 2000-06-05 JP JP2001502467A patent/JP2003501443A/ja active Pending
- 2000-06-05 RU RU2002100069/04A patent/RU2263680C2/ru not_active IP Right Cessation
- 2000-06-05 CZ CZ20014297A patent/CZ20014297A3/cs unknown
- 2000-06-05 BR BR0011680-7A patent/BR0011680A/pt not_active Application Discontinuation
- 2000-06-05 PL PL00352968A patent/PL352968A1/xx not_active Application Discontinuation
- 2000-06-29 TW TW089110978A patent/TWI243177B/zh active
-
2005
- 2005-05-19 RU RU2005115448/04A patent/RU2005115448A/ru not_active Application Discontinuation
- 2005-05-19 RU RU2005115449/04A patent/RU2005115449A/ru not_active Application Discontinuation
-
2008
- 2008-11-12 JP JP2008290079A patent/JP5165537B2/ja not_active Expired - Fee Related
-
2011
- 2011-12-02 JP JP2011264477A patent/JP5519622B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1189941B1 (en) | 2013-01-09 |
CA2376506A1 (en) | 2000-12-14 |
CA2376506C (en) | 2014-07-22 |
PL352968A1 (en) | 2003-09-22 |
HUP0202022A2 (en) | 2002-10-28 |
JP2003501443A (ja) | 2003-01-14 |
RU2005115449A (ru) | 2006-11-20 |
IL146884A0 (en) | 2002-08-14 |
JP5165537B2 (ja) | 2013-03-21 |
JP5519622B2 (ja) | 2014-06-11 |
AU5463300A (en) | 2000-12-28 |
RU2263680C2 (ru) | 2005-11-10 |
BR0011680A (pt) | 2002-04-30 |
AR020862A1 (es) | 2002-05-29 |
HUP0202022A3 (en) | 2003-10-28 |
TWI243177B (en) | 2005-11-11 |
JP2009108078A (ja) | 2009-05-21 |
JP2012102103A (ja) | 2012-05-31 |
CN1367793A (zh) | 2002-09-04 |
EP1189941A1 (en) | 2002-03-27 |
CZ20014297A3 (cs) | 2002-06-12 |
WO2000075186A1 (en) | 2000-12-14 |
ES2401096T3 (es) | 2013-04-16 |
AU774096B2 (en) | 2004-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2005115448A (ru) | Агонисты рецепторов нейромедина в и соматостатина | |
JP5254868B2 (ja) | ソマトスタチン−ドーパミンキメラ類似体 | |
KR100247212B1 (ko) | 성장 호르몬 방출활성을 갖는 펩티드 | |
CA1182109A (en) | Polypeptides, processes for their production, pharmaceutical compositions comprising said polypeptides and their use | |
EP0400051B1 (en) | Polypeptide compounds having growth hormone releasing activity | |
JP2007224033A (ja) | ソマトスタチン−ドーパミンキメラ類似体 | |
CA2921324C (en) | Cortistatin analogues for the treatment of inflammatory and/or immune diseases | |
WO2004067548A2 (en) | Chemically modified metabolites of regulatory peptides and methods of producing and using same | |
RU2003132548A (ru) | Агонисты соматостатина | |
JP2004531520A5 (ru) | ||
CA2760977A1 (en) | Peptide ligands of somatostatin receptors | |
WO1992001711A1 (en) | Polypeptide compounds having growth hormone releasing activity | |
RU2002100069A (ru) | Агонисты рецепторов нейромедина в и соматостатина | |
RU2002101732A (ru) | Агонисты соматостатина | |
EP1189942A1 (en) | Somatostatin agonists | |
EP0663834A1 (en) | Growth hormone releasing peptides | |
RU2020136592A (ru) | Синтез ликсисенатида с кэппированием | |
JP2003174889A5 (ru) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20080620 |